Needham & Company Reiterates a 'Buy' on AtriCure (ATRC); Positive Takeaways from ISMICS

Needham & Company reiterates a 'Buy' on AtriCure Inc. (NASDAQ: ATRC), PT raised to $17.

Needham analyst says, "We attended the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) conference late last week in Washington, D.C., and also got a chance to meet with management. We remain bullish regarding management’s aptitude to pursue multiple growth opportunities as well as focus on several regulatory approvals and new product development/launches. We believe ATRC continues to fire on all cylinders, and we would characterize the energy and commitment level throughout the organization as high."

For more ratings news on AtriCure Inc. click here and for the rating history of AtriCure Inc. click here.

Shares of AtriCure Inc. closed at $13.99 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Alpha & Omega Semiconductor (AOSL) PT Lowered to $45 at Needham
• Cellebrite (CLBT) PT Lowered to $12.50 at Needham